JPS6429319A - Antiviral agent containing lysolecithin and phospholipid - Google Patents

Antiviral agent containing lysolecithin and phospholipid

Info

Publication number
JPS6429319A
JPS6429319A JP62182365A JP18236587A JPS6429319A JP S6429319 A JPS6429319 A JP S6429319A JP 62182365 A JP62182365 A JP 62182365A JP 18236587 A JP18236587 A JP 18236587A JP S6429319 A JPS6429319 A JP S6429319A
Authority
JP
Japan
Prior art keywords
lysolecithin
antiviral agent
phospholipid
lipid
state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62182365A
Other languages
Japanese (ja)
Inventor
Isamu Saikawa
Takako Hori
Yosuke Furuta
Yoshifumi Nakajima
Shuntaro Takano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyama Chemical Co Ltd
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Priority to JP62182365A priority Critical patent/JPS6429319A/en
Publication of JPS6429319A publication Critical patent/JPS6429319A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE:To obtain an effective antiviral agent having low toxicity and strongly fluidizing action on membrane, containing a lysolecithin and a phospholipid. CONSTITUTION:An antiviral agent containing a lysolecithin shown by the formu la (one of R<1> and R<2> is 14-18C alkanoyloxy and the other is OH) and a phospho lipid (egg yolk lecithin) in the ratio of 1-500pts.wt., especially 5-20pts.wt. phospholipid based on 1pt.wt. lysolecithin. The antiviral agent may be a mere blend of constituent components or a dispersion in a micellar state or an endo plasmic reticulum state of lipid and especially preferably in an endoplasmic reticulum state of lipid, having <=1mu, especially <=0.5mu particle diameter. The antiviral agent shows antiviral activity against viruses having envelope and usually a drug containing 0.1-200mg/kg lysolecithin is orally or parenterally administered daily per adult once four times.
JP62182365A 1987-07-23 1987-07-23 Antiviral agent containing lysolecithin and phospholipid Pending JPS6429319A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62182365A JPS6429319A (en) 1987-07-23 1987-07-23 Antiviral agent containing lysolecithin and phospholipid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62182365A JPS6429319A (en) 1987-07-23 1987-07-23 Antiviral agent containing lysolecithin and phospholipid

Publications (1)

Publication Number Publication Date
JPS6429319A true JPS6429319A (en) 1989-01-31

Family

ID=16117038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62182365A Pending JPS6429319A (en) 1987-07-23 1987-07-23 Antiviral agent containing lysolecithin and phospholipid

Country Status (1)

Country Link
JP (1) JPS6429319A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416401A2 (en) * 1989-09-02 1991-03-13 Roche Diagnostics GmbH Use of derivatives of phospholipides as antiviral pharmaceuticals and phospholipides
WO1994000131A1 (en) * 1992-06-24 1994-01-06 Tokyo Tanabe Company Limited Prophylactic and remedy for viral diseases in respiratory tract
WO1994028908A2 (en) * 1993-06-10 1994-12-22 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
FR2745184A1 (en) * 1996-02-28 1997-08-29 Chanseau Sylvain Use of soya lecithin as product to combat AIDS
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
WO2015199456A1 (en) * 2014-06-25 2015-12-30 한국생명공학연구원 Antiviral composition containing material involved in phosphatidylcholine synthesis pathway

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614548A (en) * 1988-10-25 1997-03-25 Wake Forest University Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
EP0416401A2 (en) * 1989-09-02 1991-03-13 Roche Diagnostics GmbH Use of derivatives of phospholipides as antiviral pharmaceuticals and phospholipides
WO1994000131A1 (en) * 1992-06-24 1994-01-06 Tokyo Tanabe Company Limited Prophylactic and remedy for viral diseases in respiratory tract
US5770584A (en) * 1993-06-10 1998-06-23 Wake Forest University Method of treating hepatitis virus infections
WO1994028908A3 (en) * 1993-06-10 1995-03-23 Univ Wake Forest (phospho)lipids for combatting hepatitis b virus infection
WO1994028908A2 (en) * 1993-06-10 1994-12-22 Wake Forest University (phospho)lipids for combatting hepatitis b virus infection
US6030960A (en) * 1993-06-10 2000-02-29 Wake Forest University Method of treating hepatitis virus infections
US5962437A (en) * 1994-08-29 1999-10-05 Wake Forest University Lipid analogs for treating viral infections
US7129227B1 (en) 1994-08-29 2006-10-31 Wake Forest University Lipid analogs for treating viral infections
FR2745184A1 (en) * 1996-02-28 1997-08-29 Chanseau Sylvain Use of soya lecithin as product to combat AIDS
WO2015199456A1 (en) * 2014-06-25 2015-12-30 한국생명공학연구원 Antiviral composition containing material involved in phosphatidylcholine synthesis pathway
KR20160000751A (en) * 2014-06-25 2016-01-05 한국생명공학연구원 Anti-viral composition comprising compounds related to phosphatidylcholine synthetic pathway
US10092587B2 (en) 2014-06-25 2018-10-09 Korea Research Institute Of Bioscience And Biotechnology Antiviral composition containing material involved in phosphatidylcholine synthesis pathway

Similar Documents

Publication Publication Date Title
ES8607906A1 (en) Process for preparing pharmaceutical compositions containing unilamellar liposomes.
ES8708185A1 (en) Microemulsion compositions.
AU3046495A (en) Injectable liposomal pharmaceutical preparations
JPS6429319A (en) Antiviral agent containing lysolecithin and phospholipid
JPS56167616A (en) Steroid preparation
AU1534088A (en) Pesticidal formulations comprising an active ingredient or an emulsion and one or more active ingredients formed as suspensions
CA2095889A1 (en) Low caloric density enteral formulation designed to reduce diarrhea in tube-fed patients
EP0209037A1 (en) Pharmaceutical compositions containing flavanolignanes and phospholipids as active principles
JPS5793910A (en) Preparation of emulsion for intravenous injection
KR900701174A (en) Phospholipid-containing compositions, methods for their preparation and use as excipients for pharmaceutical substances
IT1212900B (en) THERAPEUTIC USE OF PHOSPHATIDYLSERINE IN DISEASES OF THE CENTRAL NERVOUS SYSTEM WITHOUT EFFECTS ON BLOOD COAGULATION
AU720209B2 (en) Solvent detergent emulsions having antiviral activity
ES2086802T3 (en) LIPOSOMIC FORMULATIONS OF ACTIVE PRINCIPLES AND PROCEDURE FOR THE PREPARATION.
GR3015290T3 (en) Phospholipid delivery vehicle for aqueous-insoluble active ingredients.
AU584122B2 (en) Metered dose aerosol of nifedipin
AU7806187A (en) Sulphonamide derivatives for the treatment and prevention of viral diseases
IE831482L (en) Stabilizing memadione and thiamine
Radany et al. The incorporation of a purified, membrane-bound form of guanylate cyclase into phospholipid vesicles and erythrocytes
JPS5731614A (en) Lipid improver
ATE98479T1 (en) MEDICINAL LIPID COMPOSITION FOR PARENTERAL FOOD.
程昆蓉 et al. EFFECTS OF CYTOCHROME C ON THE NONBILAYER PHASE TRANSITION OF CARDIOLIPIN
EP0333678A3 (en) Use of glycerol ethers in the treatment of allergic diseases
Reynolds et al. THE UPTAKE AND ACETYLATION OF STRAINS OF MICE
EP1007022B1 (en) Preparation of a pulmonary surfactant for instillation and oral application
RU94027343A (en) Cytochrome c-containing liposomal vesicle